PURPOSE: The effects of omeprazole on indinavir when administered alone or in combination with ritonavir were evaluated. METHODS:Fourteen men and women age 18-55 years not infected with human immunodeficiency virus who met study qualifications were randomized to receive placebo, 20 mg of omeprazole, or 40 mg of omeprazole daily. After seven days, the single-dose pharmacokinetic profile of an 800-mg dose of indinavir alone or in combination with 200 mg of ritonavir was evaluated. Study participants received each of four study regimens in one of four randomly assigned orders. Blood samples were collected, and plasma indinavir and ritonavir concentrations were analyzed using high-performance liquid chromatography. RESULTS: The coadministration of 20 or 40 mg of omeprazole with indinavir significantly reduced the mean indinavir area under the concentration-versus-time curve (AUC) from 30.0 mg x hr/L (95% confidence interval [CI], 21.9-41.1 mg x hr/L) to 19.7 mg x hr/L (95% CI, 14.6-26.8 mg x hr/L) or 16.0 mg x hr/L (95% CI, 11.8-21.7 mg x hr/L), respectively (p < 0.002). The addition of 200 mg of ritonavir to 800 mg of indinavir in combination with 40 mg of omeprazole significantly increased the mean indinavir AUC from 30.0 mg x hr/L (95% CI, 21.9-41.1 mg x hr/L) to 46.6 mg x hr/L (95% CI, 34.0-63.8 mg x hr/L), but it did not significantly affect mean omeprazole concentrations (p < or = 0.02). CONCLUSION: The AUC of indinavir was substantially decreased in healthy volunteers who received omeprazole 20 or 40 mg daily for seven days before the administration of a single 800-mg dose of indinavir. Concomitant administration of ritonavir 200 mg with indinavir in participants receivingomeprazole led to a significant increase in the AUC of indinavir.
RCT Entities:
PURPOSE: The effects of omeprazole on indinavir when administered alone or in combination with ritonavir were evaluated. METHODS: Fourteen men and women age 18-55 years not infected with human immunodeficiency virus who met study qualifications were randomized to receive placebo, 20 mg of omeprazole, or 40 mg of omeprazole daily. After seven days, the single-dose pharmacokinetic profile of an 800-mg dose of indinavir alone or in combination with 200 mg of ritonavir was evaluated. Study participants received each of four study regimens in one of four randomly assigned orders. Blood samples were collected, and plasma indinavir and ritonavir concentrations were analyzed using high-performance liquid chromatography. RESULTS: The coadministration of 20 or 40 mg of omeprazole with indinavir significantly reduced the mean indinavir area under the concentration-versus-time curve (AUC) from 30.0 mg x hr/L (95% confidence interval [CI], 21.9-41.1 mg x hr/L) to 19.7 mg x hr/L (95% CI, 14.6-26.8 mg x hr/L) or 16.0 mg x hr/L (95% CI, 11.8-21.7 mg x hr/L), respectively (p < 0.002). The addition of 200 mg of ritonavir to 800 mg of indinavir in combination with 40 mg of omeprazole significantly increased the mean indinavir AUC from 30.0 mg x hr/L (95% CI, 21.9-41.1 mg x hr/L) to 46.6 mg x hr/L (95% CI, 34.0-63.8 mg x hr/L), but it did not significantly affect mean omeprazole concentrations (p < or = 0.02). CONCLUSION: The AUC of indinavir was substantially decreased in healthy volunteers who received omeprazole 20 or 40 mg daily for seven days before the administration of a single 800-mg dose of indinavir. Concomitant administration of ritonavir 200 mg with indinavir in participants receiving omeprazole led to a significant increase in the AUC of indinavir.
Authors: Marta Boffito; Pierluigi Carriero; Laura Trentini; Riccardo Raiteri; Stefano Bonora; Alessandro Sinicco; Helen E Reynolds; Patrick G Hoggard; David J Back; Giovanni Di Perri Journal: J Antimicrob Chemother Date: 2002-12 Impact factor: 5.790
Authors: Naser L Rezk; Richard R Tidwell; Angela D M Kashuba Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2004-06-15 Impact factor: 3.205
Authors: D M Burger; P W Hugen; F P Kroon; P Groeneveld; K Brinkman; N A Foudraine; H Sprenger; P P Koopmans; Y A Hekster Journal: AIDS Date: 1998-10-22 Impact factor: 4.177
Authors: A J Saah; G A Winchell; M L Nessly; M A Seniuk; R R Rhodes; P J Deutsch Journal: Antimicrob Agents Chemother Date: 2001-10 Impact factor: 5.191
Authors: P W Hugen; D M Burger; H J ter Hofstede; P P Koopmans; M Stek; Y A Hekster; P Reiss; J M Lange Journal: J Acquir Immune Defic Syndr Date: 2000-11-01 Impact factor: 3.731
Authors: Eric S Furfine; Christopher T Baker; Michael R Hale; David J Reynolds; Jo A Salisbury; Andy D Searle; Scott D Studenberg; Dan Todd; Roger D Tung; Andrew Spaltenstein Journal: Antimicrob Agents Chemother Date: 2004-03 Impact factor: 5.191
Authors: Monika Schöller-Gyüre; Thomas N Kakuda; Goedele De Smedt; Hilde Vanaken; Marie-Paule Bouche; Monika Peeters; Brian Woodfall; Richard M W Hoetelmans Journal: Br J Clin Pharmacol Date: 2008-04-25 Impact factor: 4.335